Pharmacodynamic effects of cangrelor in elective complex PCI: insights from the POMPEII Registry.
Giuseppe Gargiulo, Alessandra Marenna, Luca Sperandeo, Lina Manzi, Marisa Avvedimento, Fiorenzo Simonetti, Mario Enrico Canonico, Roberta Paolillo, Alessandra Spinelli, Francesco Borgia, Luigi Di Serafino, Anna Franzone, Eugenio Stabile, Raffaele Piccolo, Plinio Cirillo, Marco Valgimigli, Giovanni Esposito
Abstract
The PharmacOdynaMic effects of cangrelor in PatiEnts wIth acute or chronIc coronary syndrome undergoing percutaneous coronary intervention (POMPEII) registry (ClincalTrials.gov: NCT04790032) is a prospective study conducted at Federico II University of Naples enrolling all patients undergoing PCI with cangrelor. Pharmacodynamic data show that cangrelor might be a useful option for a fast platelet inhibition during complex PCI, but caution should be paid to a potential rebound effect at the end of its infusion while the oral P2Y12 effect is not yet achieved.